User Fees Should Support Post-Market Safety, Consumer Groups Say
This article was originally published in The Gray Sheet
Executive Summary
Medical and consumer groups say future user fees should go toward ensuring device safety, not just toward speeding up product approvals.
You may also be interested in...
Medical Device User Fee Negotiations: Here We Go Again
FDA is holding a meeting Sept. 14 to start a public dialogue on the next reauthorization of medical device user fees, more than two years before Congress needs to renew the program
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.